Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Journal of the American Academy of Dermatology Jan 19, 2018
Simpson EL, et al. - As a part of this research, the efficacy and safety of lebrikizumab (anti-IL-13 monoclonal antibody) as an add-on to topical corticosteroid (TCS) were inspected in adults with moderate-to-severe atopic dermatitis (AD). A substantial improvement was achieved in the study cohort due to lebrikizumab 125 mg once every 4 weeks (Q4W) when added to TCS. It was found to be well tolerated.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
